[Biological treatment in dermatology--psoriasis]. / Biologická lécba v dermatologii--psoriáza.
Vnitr Lek
; 57(9): 684-92, 2011 Sep.
Article
en Cs
| MEDLINE
| ID: mdl-21957759
Psoriasis is a chronic, relapsing skin disease affecting 1-2% of the population. Genetically-determined autoimmune inflammation is initiated by an infection (e.g. streptococcal). T-lymphocytes, producing a number ofcytokines, mainly of the Th1 profile, including TNF alpha, play a key role. The role of Th17 and its interleukin IL-23 has recently been confirmed. It contains p40 protein, also a component of IL-12. TNF alpha and p40 blockade appear to be an effective biological treatment of severe lesional psoriasis. Further research and new drug development is to assure modern individualized treatment of psoriasis as well as other skin diseases.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Anticuerpos Monoclonales
Límite:
Humans
Idioma:
Cs
Revista:
Vnitr Lek
Año:
2011
Tipo del documento:
Article